Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 1999

View Archived Issues

Positive study results obtained for Andrographolide + AZT

Cortecs discontinues Macritonin development and refocuses resources

Viagra is effective in treating ED in men with depression

NCI scientists on track to develop a vaccine to prevent, treat genital warts and cervical cancer

CombiChem and Icos expand collaboration

AxyS initiates phase II human clinical trials of APC-2059 for treatment of psoriasis

Matrix broadens phase II clinical trial program for FMdC to include colorectal cancer

Maxygen receives milestone payment from Pfizer

BioMarin subsidiary acquires biochemical reagent business from Oxford GlycoSciences

Significant antitumor response shown in preclinical study of prostate cancer treatment

News from DDW: effects of a 5-HT4 receptor antagonist on GI function in volunteers

Astressin B: a potential treatment for stress-induced gastrointestinal disturbances

Alza submits NDA for Viadur prostate cancer treatment

Bayer and Takeda launch cerivastatin in Japan

Zelmac featured in multiple presentations at DDW

Cenestin expected to be available in pharmacies by June 1, 1999

New compounds synthesized at JT promote osteogenesis

Cephalon develops compounds for muscle wasting

DNA ligase inhibitors with alpha-pyrone structure in development at Millennium

Dopamine D4 receptor ligands useful for schizophrenia claimed by Neurogen and Schering-Plough

Merck's new carbapenems particularly active against methicillin-resistant Gram-positive pathogens

Pierre Fabre strengthens R&D programs; company pipeline in review

Novel bicyclic compounds useful for lipid disorders, diabetes, obesity, etc.

New antifungal azole compounds developed in China

Potent new quinolone antibacterial agents synthesized at Shanghai Institute of Materia Medica

New gerontogene discovered by GenoPlex; further study funded by NIH

Survival advantage for exemestane observed in phase III breast cancer trial reported at ASCO meeting

RotaShield vaccine receives marketing authorization in Europe

PD-098059 inhibits AII-induced MAPK activation in myocardial cells

Long-term AT1 receptor blockade with fonsartan proves highly beneficial in SHR-SP

More news from ASCO: safety and pharmacokinetics of squalamine examined in phase I trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...